# A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.

> **NCT03863483** · PHASE2 · UNKNOWN · sponsor: **Xin-Hua Xu** · enrollment: 70 (estimated)

## Conditions studied

- Nonsquamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Docetaxel
- **DRUG:** Pemetrexed
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03863483
- **Lead sponsor:** Xin-Hua Xu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-26
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2021-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03863483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03863483, "A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03863483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*